Gantenbein, Andreas R; Bonvin, Christophe; Kamm, Christian P; Schankin, Christoph J; Zecca, Chiara; Zieglgänsberger, Dominik; Merki-Feld, Gabriele Susanne; Pohl, Heiko; Rudolph, Nicole; Ryvlin, Philippe; Agosti, Reto; Schäfer, Elisabeth; Meyer, Ina; Kulartz-Schank, Monika; Arzt, Michael E (2024). Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. Journal of neurology, 271(8), pp. 5402-5410. Springer 10.1007/s00415-024-12470-6
|
Text
s00415-024-12470-6.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
BACKGROUND
There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.
OBJECTIVE
This 18-month interim analysis of 172 patients with episodic or chronic migraine from the SQUARE study provides first prospective insights on the impact of mandatory erenumab treatment interruption, following Swiss-reimbursement requirements, in a real-world clinical setting in Switzerland.
FINDINGS
Recruited patients receiving 70 or 140 mg erenumab underwent treatment interruption on average 11.2 months after therapy onset with a mean duration of 4 months. There were sustained improvements in mean monthly migraine days (MMD) and migraine disability (mMIDAS) during initial treatment with erenumab. Treatment interruption was associated with a temporary worsening of condition. Symptoms ameliorated upon therapy reuptake reaching improvements similar to pre-break within 3 months.
CONCLUSIONS
Treatment interruption was associated with a temporary worsening of condition, which improved again after therapy restart.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology |
UniBE Contributor: |
Kamm, Christian Philipp, Schankin, Christoph Josef |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1432-1459 |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
20 Jun 2024 09:22 |
Last Modified: |
13 Aug 2024 00:15 |
Publisher DOI: |
10.1007/s00415-024-12470-6 |
PubMed ID: |
38871822 |
Uncontrolled Keywords: |
Break CGRP Erenumab Migraine RWE Real world evidence |
BORIS DOI: |
10.48350/197833 |
URI: |
https://boris.unibe.ch/id/eprint/197833 |
Actions (login required)
 |
Edit item |